Rasagiline + Pramipexole
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Early-stage Parkinson's Disease
Conditions
Early-stage Parkinson's Disease
Trial Timeline
Oct 1, 2008 → Mar 1, 2010
NCT ID
NCT01048229About Rasagiline + Pramipexole
Rasagiline + Pramipexole is a approved stage product being developed by Lundbeck for Early-stage Parkinson's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01048229. Target conditions include Early-stage Parkinson's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01048229 | Approved | Terminated |
Competing Products
9 competing products in Early-stage Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| ICG | Johnson & Johnson | Pre-clinical | 23 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 77 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| UCB0599 + Placebo | UCB | Phase 2 | 49 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 44 |